(Q43218793)

16 November 2017

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing (English)

1 reference

16 November 2017

1 reference

1 reference

4

1 reference

16 November 2017

Lisa M Meckley

1

0 references

author name string

James M Gudgeon

series ordinal

2

1 reference

16 November 2017

Jeffrey L Anderson

series ordinal

3

1 reference

16 November 2017

David L Veenstra

series ordinal

5

1 reference

16 November 2017

1 January 2010

1 reference

16 November 2017

1 reference

16 November 2017

28

1 reference

16 November 2017

61-74

1 reference

16 November 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/11318240-000000000-00000

16 November 2017

0 references

cites work

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.2165%2F11318240-000000000-00000

Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318240-000000000-00000

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318240-000000000-00000

Generalisability in economic evaluation studies in healthcare: a review and case studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318240-000000000-00000

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

12 December 2020

A method to determine the optimal intensity of oral anticoagulant therapy.

1 reference

12 December 2020

Preference-Based EQ-5D index scores for chronic conditions in the United States

1 reference

12 December 2020

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

1 reference

12 December 2020

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin

1 reference

12 December 2020

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

12 December 2020

Warfarin pharmacogenetics: economic considerations.

1 reference

12 December 2020

The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US

1 reference

12 December 2020

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

1 reference

12 December 2020

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

1 reference

12 December 2020

Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis

1 reference

12 December 2020

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

12 December 2020

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

1 reference

12 December 2020

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy

1 reference

12 December 2020

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

1 reference

12 December 2020

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

1 reference

12 December 2020

The incidence of adverse drug events in two large academic long-term care facilities

1 reference

12 December 2020

The cost-effectiveness of warfarin pharmacogenomics

1 reference

12 December 2020

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

1 reference

12 December 2020

Death and disability from warfarin-associated intracranial and extracranial hemorrhages

1 reference

12 December 2020

Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making

1 reference

12 December 2020

CYP4F2 genetic variant alters required warfarin dose

1 reference

12 December 2020

Utilization of acute care services in the year before and after first stroke: A population-based study.

1 reference

12 December 2020

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

1 reference

12 December 2020

Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization

1 reference

12 December 2020

Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management.

1 reference

12 December 2020

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

12 December 2020

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

1 reference

12 December 2020

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

1 reference

12 December 2020

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

1 reference

12 December 2020

10.2165/11318240-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference